If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Product Launch » Resource Allocation
Download FREE Excerpt
13 Info Graphics
112 Data Graphics
3 Best Practices
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Also, organizations often pursue a second indication for the same oncology product in order to not only expand a product's patient base but also to leverage savings on launch investment by using infrastructure and resources from the first indication launch.
Best Practices, LLC undertook benchmarking research to inform oncology launch teams with evidence-based benchmarks around investment, staffing and timing requirements to successfully launch new oncology drugs in the U.S. market.
In particular, the report benchmarks investment levels at each launch stage as well as budget and staffing allocation across critical Medical and Commercial activities for various market-entry situations or market-entry archetypes: portfolios featuring multiple molecules which treat single or multiple indications, and portfolios using single molecules to treat individual cancer types. It also probes key U.S. oncology market-entry trends and success factors and explores the synergy or franchise effects where multiple oncology products and indications create lift through shared infrastructure.
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Health Care
Astellas; Bayer; EMD Serono; Lilly; Medivation; Nektar Therapeutics; Novartis; OTSUKA; Pfizer; Regeneron; Tesaro; Amgen
This research probes oncology product investment levels for 12 companies and 20 U.S. project launches across pre-launch, launch and post-launch periods to inform U.S. Oncology Launch teams in each of the following key intelligence areas:
I. Peak Year Sales Forecasting
Medical Affairs consume three times as many FTE resources as marketing in Year -2. In fact, Medical Affairs is the largest staffing category in that timeframe. Medical Affairs adds staff starting from Year -3 and drastically increases personnel in Year -1.
Market access spending jumps significantly (up to the 4th highest spend area) during Year -1.
Sales, medical affairs, and managed markets staff all jump up in Launch Year. One year post-launch, sales and managed markets staffing levels peak. Brand-specific marketing FTEs increase steadily, peaking during the Launch Year.